Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone

Cesáreo Ángel Trueba Davalillo1,2
Cesáreo Trueba Vasavilbaso2
José Mario Navarrete Álvarez2
Pilar Coronel Granado3
Ozcar Alejandro García Jiménez2
Mercedes Gimeno del Sol3
Félix Gil Orbezo2

1School of Medicine (UNAM), México DF, Mexico; 2Orthopedic Service, Hospital Español de México, México DF, Mexico; 3Scientific Department, TEDEC-MEIJI FARMA,SA, Alcalá de Henares, Spain

Background: Osteoarthritis (OA) is the most common joint disease and leading cause of disability. Intra-articular (IA) administration of hyaluronic acid (HA) or corticosteroids (CS) have been previously studied, though using insufficient number of patients or short follow-up periods.

Objective: We evaluate HA and CS in patients with knee OA in terms of clinical efficacy over 12 months.

Methods: We used a prospective, randomized study with parallel groups. Randomized patients received IA injections of HA or betamethasone (BM). The primary outcomes were improvement in pain using Visual Analog Scale and function in the Western Ontario and McMaster University Osteoarthritis Index (Likert scale). Follow-up visits were scheduled at 3 months, 6 months, 9 months, and 12 months.

Results: A total of 200 patients were included. Pain was significantly reduced in both groups at the first follow-ups. At 12 months, the mean pain reduction in the HA group was 33.6% (95% CI: 31.1–36.1) compared to 8.2% (95% CI: 5.2–11.1) in BM (P<0.0001). Function improvement was higher in HA through every visit, and mean improvement at 12 months was 47.5% (95% CI: 45.6–49.3) in HA patients vs 13.2% (95% CI: 11.4–14.9) in the BM group (P<0.0001). All patients from both groups achieved the Minimal Clinically Important Improvement (MCII) for both pain and function up to 6 months. At 9 months and 12 months, the MCII figures were higher in HA group with ≥80% compared to ≤10% in BM group (P<0.0001). Adverse reactions were rare and related to the administration procedure.

Conclusion: Both treatments effectively controlled OA symptoms. BM showed higher short-term effectiveness, while HA showed better long-term effectiveness, maintaining clinical efficacy in a large number of patients 1 year after administration.

Keywords: viscosupplementation, corticosteroids, knee injection, joint disease

Introduction
Osteoarthritis (OA) is the most common form of joint disease and a leading cause of disability in the elderly. The main large joint affected is the knee, and a recent report found that symptomatic knee OA occurs in 10% of men and 13% of women aged 60 years or more.

The etiology is multifactorial, including a variety of risk factors (aging, genetics, trauma, malalignment, and obesity), which interact to cause this disorder. The primary objectives in OA treatment focus on pain reduction, joint mobility improvement, and functional impairment limitation. Furthermore, secondary goals are centered on the reduction of disease progression and improvement of muscular
strength, in order to preserve patients’ independence and quality of life.³

Despite the immense impact of this disease, very few effective nonsurgical options are available to handle it. Current treatment guidelines⁴–⁷ recommend starting by using nonpharmacological measures such as patient education, weight loss, and physical therapy. Nevertheless, it is commonly accepted that the optimal management of knee OA requires a combination of nonpharmacologic and pharmacologic treatments, such as acetaminophen, nonsteroidal anti-inflammatory drugs, or selective COX2 inhibitors.

An alternative to oral drugs for pain in patients with low response to analgesics and/or anti-inflammatory drugs, or with contraindications to them, is the use of intra-articular (IA) therapy.⁸ IA treatment is of special interest not only for pain relief and pain flares in more acute situations but also to delay any surgical intervention by improving the patients’ subjective quality of life.⁹ Nowadays, two widely accepted products are being used for IA injections: hyaluronic acid (HA) and corticosteroids (CS).

CS knee injections have been in use for the last 60 years in the conservative management of OA, and they are recommended in several consensus documents⁴–⁷ as a useful adjunctive treatment for it.¹⁰ A major Cochrane review¹¹ evaluated the efficacy and safety of IA CS in the treatment of knee OA. The authors concluded that it appears the beneficial effects of IA CS are fast at onset but may be relatively short-lived (1–3 weeks); in addition, there was no evidence of long-term efficacy. In spite of the numerous publications concerning the use of IA CS, there is hardly any agreement on the most efficacious dose and dosing regimen of these agents.¹²

Since Balazs and Delinger started their works of viscosupplementation with HA,¹³ this compound has been widely used as a nonsurgical alternative to treat OA until today. HA is a key molecule in joint biomechanics because of the fact that the treatment with exogenous HA contributes to the restoration of the elastic and viscous properties of the synovial fluid, resulting in pain reduction and functional improvement. Moreover, different studies have confirmed that HA interacts with inflammation mediators and matrix turnover in joint cells, reduces the apoptosis of chondrocytes, and exerts a biosynthetic-chondroprotective effect.¹⁴–¹⁸ The use of viscosupplementation is also recommended by various scientific societies.⁵–⁷

Several clinical studies have been conducted comparing face to face HA and CS in knee OA.¹⁹–²⁸ However, very often they included a small number of patients or had a short follow-up. A meta-analysis comparing CS and HA showed a pattern of efficacy that varied over time, and concluded that, beyond 8 weeks after injection, HA had greater efficacy.⁹ Nevertheless, other studies,²⁴–²⁸ some of them published after the meta-analysis, did not find significant differences in clinical effects between CS and HA at 3 months or even at 6 months’ follow-up, leaving open the discussion on the relative efficacy of the two products. Taking the available information into account, we found it of interest to conduct a clinical trial in order to compare HA with a CS, betamethasone (BM), evaluating both treatments in terms of clinical efficacy and enlarging the follow-up period up to 12 months.

Material and methods

Ethics

The study was performed in accordance to the principles of Good Clinical Practice guidelines and in compliance with the Declaration of Helsinki. The protocol was approved by the local Ethics Review Board from Hospital Español de México, and all patients gave written informed consent to participate in the study.

Design

This was a prospective, randomized, open study with parallel groups. Patients suffering from knee OA were randomized to receive IA injections of 2.5 mL of 1% HA with a mean molecular weight of 900,000 Da, obtained by a fermentation process from Streptococcus zoopidemicus strains (Suprahyl®) or IA injections of BM: BM diphosphate 5.0 mg + BM sodium phosphate 2.0 mg in 1 mL (Diprosan Hypack®).

The treatment consisted of five IA injections of HA (day 0 and weekly injections afterward) or two injections of BM (day 0 and in the fourth week), and the follow-up visits were scheduled at 3 months, 6 months, 9 months, and 12 months.

Prior to inclusion, patients were assessed for fulfillment of the entry criteria, and eligible patients were informed about the study purpose and the study design. Demographic characteristics and medical history of the participants were recorded, and laboratory tests were done. X-ray of both knees was performed using anteroposterior projection with support, lateral with 30° flexion and Merchant (45°) views, as well as one bipodalic mechanical axis digitalized in a single plate.

Eligible patients were randomized 1:1. In this study, a computer-generated list of random numbers was used. The random sequence was created using the freely accessible tools available at http://www.randomization.com, which uses the pseudo-random number generator of Wichmann
and Hill and modified by McLeod. This tool allows the introduction of several treatments or intervention arms, and includes a seed for the random number generator that allows exact reproduction of the randomization schedule of the study any time and when details and labels are introduced in the same way.

The allocation sequence was concealed from the people determining the patient’s eligibility at the initial visit. Once the eligibility of the patient was confirmed, a number was given, and a different person was responsible for the patient’s assignment to treatment according to the randomization list. The physician in charge of evaluations at follow-up was blind to patient’s group assignment, whereas the patients and the personnel administering the injections were not blinded. Administration of the IA treatments took place under aseptic conditions by inserting the needle into the patellofemoral joint space by superolateral approach, with the patients in a supine position. Arthrocentesis was performed prior to each injection in order to remove any effusion. In case of bilateral affection, both knees were treated with the same product.

Concomitantly to the administration of IA injections, the patients of both groups initiated treatment with glucosamine sulfate 1500 mg meloxicam 15 mg for 1 month. Once completed, the patients were prescribed glucosamine sulfate 1500 mg chondroitin sulfate 1200 mg for one additional month. In case of continued pain during the follow-up, paracetamol was the only treatment allowed, up to 3 g/day.

**Patients selection criteria**

Eligible patients were men and women from 40 years to 85 years of age suffering from knee OA, with radiographic OA grade II–III according to Kellgren and Lawrence (KL) with a body mass index (BMI) <35 kg/m², who had signed the informed consent form for participation.

Main exclusion criteria were a history of trauma or surgery on the target knee, inflammatory arthritis, microcrystalline arthropathies, previous unspecific knee synovitis, knee infection, angular deformity >10°, and neoplasia, as well as other conditions where the administration of CS would be specifically contraindicated such as diabetes mellitus, and metabolic syndrome.

**Evaluation of efficacy**

The primary efficacy outcomes were reduction in global pain and function improvement using Western Ontario McMaster University Osteoarthritis (WOMAC) subscale at the end of follow-up (12 months), in comparison to baseline and the difference between both treatment groups. A 0–10 cm Visual Analog Scale (VAS) was used for global pain measurement, and a five-point Likert scale (0–4) for WOMAC. For both VAS and Likert scales, the higher the score, the worse is the patient’s condition.

The WOMAC questionnaire used was the translated version from Batlle-Gualda et al,22 validated by Escobar et al.31

Efficacy along the different visits scheduled in the protocol and consumption of acetaminophen as rescue medication for OA were assessed as secondary outcomes.

Additionally, the number of patients achieving the Minimal Clinically Important Improvement (MCII) on each treatment group was also calculated. The MCII is the smallest change in measurement that signifies an important improvement in a patient’s symptom. In our study, we used as reference the work of Tubach et al,33 which established the MCII as the 75th percentile of the distribution of change in patient-reported outcomes scores for patients who considered they had slight or moderate improvement. The authors concluded that their work allowed promoting the use of MCII values, which were defined as 15 of 100 for absolute improvement and 20% for relative improvement in clinical trials of rheumatic diseases, with pain, functional disability, patient global assessment, or physician global assessment used as the outcome criteria. To calculate the MCII, total scores were normalized to a 0–100 score.34

**Evaluation of safety**

The safety and tolerability of the interventions were evaluated based on the incidence and type of adverse events that could have arisen throughout the study.

**Statistics**

Categorical variables were summarized by their number and relative frequencies. Continuous variables following a normal distribution, mean, standard deviation, and maximum and minimum values were used to summarize. Alternatively, nonnormally distributed variables were summarized with their median, interquartile range, minimum, and maximum.

Comparisons in continuous variables between treatment groups were made using Student’s t-test or the Mann–Whitney U test for normally or nonnormally distributed variables, respectively. Longitudinal changes in normally distributed variables were assessed with paired t-test when two time points were compared, or with ANOVA for repeated measures for more than two. If the variables were not normally distributed, the Wilcoxon signed rank sum test and Friedman’s test
were used, instead. Categorical variable comparison between treatment groups was made through the Pearson Chi-square test (Fisher’s exact test when two dichotomous variables were compared).

The primary outcomes were defined as the changes from baseline in the raw scores of pain intensity and the WOMAC function subscale obtained by subtracting the follow-up visit value from the baseline value. These outcomes were analyzed with repeated measures of generalized linear models (GLM) from raw scores in order to include baseline values to avoid spurious associations.

The results of the primary outcomes were also analyzed by subgroups: age groups, sex, BMI, KL grade, and acetaminophen consumption. In all cases, a two-sided test with 95% confidence interval was used.

The final sample size achieved a statistical power of 96.6%, with a precision value of 95% (error type I equal to 0.05) in two groups randomized 1:1, to detect a difference of 1.5 points between groups compared to baseline.

The main population for analysis was the modified intention to treat (mITT) set, which included all randomized patients with at least one efficacy assessment after randomization. The last observation carried forward (LOCF) was used for handling missing data. The per protocol population (PP) was also analyzed and was composed of the patients who had completed the 12 months follow-up according to protocol. Safety analysis was performed in all patients who received at least one IA injection. Data were analyzed using the program STATA 11.2. All tests were two-sided, and the statistical significance was set at 0.05.

**Results**

**Disposition of patients and demographic characteristics**

Patients were recruited between April 2008 and February 2011. A total of 320 patients were screened, of whom 120 (40%) were screening failures. Five patients did not provide any efficacy data after randomization and were, therefore, not included in the analysis of efficacy, leaving a total of 195 patients in the mITT population. Finally, 89 and 91 patients receiving HA or BM, respectively, completed the study according to protocol (PP population) (Figure 1).

Within the patients, there were slightly more women (59.5%), the mean age was 62.7 years, and mean BMI was 27.1. In reference to OA condition, there were no differences between groups regarding KL grade or the knee affected (Table 1). Significant differences were found in global pain, having higher values in the BM group ($P=0.004$), and WOMAC in the HA group, due to higher scores in the function subscale ($P=0.001$) (Table 2).

**Efficacy**

In the mITT population, the raw values for pain showed a significant reduction in both groups from early follow-up (Table 2). Percentages of reduction in pain at 3 months were notably higher in the BM group (66.3%, 95% CI: 63.3–69.3) compared to the HA group (48.5%, 95% CI: 45.8–51.3) ($P<0.0001$) (Table 3); these results showed a reversion in the following visits, with the reduction in pain being significantly higher in the HA group. At 12 months, the mean reduction in pain in the HA group was 33.6% (95% CI: 31.1–36.1) compared to 8.2% (95% CI: 5.2–11.1) in patients treated with BM ($P<0.0001$). The PP population showed similar results, with the mean reduction in pain at 12 months of 34.4% (95% CI: 31.7–36.1) in the HA group and 7.7% (95% CI: 4.4–9.7) for the BM patients ($P<0.0001$). WOMAC’s total score and the subscales of pain, function, and stiffness also showed significant improvement in both treatment groups (Table 2).

When the WOMAC function scores in HA and BM at different time points were analyzed, the comparison was distinctly favorable to HA at all visits, to the extent that, at the end of the study, patients treated with HA had a mean improvement in function of 47.5% (95% CI: 45.6–49.3) compared to 13.2% (95% CI: 11.4–14.9) in the BM group ($P<0.0001$). In the PP population, these figures were 47.3% (95% CI: 46.2–48.3) and 12.0% (95% CI: 10.1–13.0), respectively ($P<0.0001$). The comparisons between groups for WOMAC’s total score, pain, and stiffness subscales followed the same pattern.

Based on the above results, the percentage of patients achieving the MCII for both pain and function was calculated. It was nearly 100% in both groups up to 6 months’ follow-up. From this visit onward, the values decreased dramatically in the BM group in such a way that at 9 months the MCII for a change of at least 15 of 100 for absolute change established in the literature was 81.4% in the HA group and only 9.2% in those treated with BM ($P<0.0001$) (Figure 2). These differences followed the same tendency when the MCII was analyzed, applying as cutoff a change of at least 20% for relative improvement: 87.6% and 10.2% ($P<0.0001$) for HA and BM, respectively (Figure 3). The results at 12 months for a decrease of at least 15 of 100 were 77.3% and 6.1% for HA and BM, respectively, and 84.5% and 5.1%, respectively, when the 20% cutoff was used (Figures 2 and 3).

In the PP population, the MCII values when the 15 of 100 cutoff for absolute improvement was used were 82.0% for HA and 5.5% for BM at 9 months, and 77.5% and 2.2%
at 12 months for HA and BM, respectively ($P<0.0001$). When the cutoff was 20% for relative improvement, the values were 88.8% for HA and 6.6% for BM at 9 months and 85.4% and 1.1% at 12 months, for HA and BM, respectively ($P<0.0001$).

The main efficacy variables (change vs baseline in global pain and WOMAC function) were analyzed using a GLM to control the effect of baseline variables that resulted in being significant, such as BMI. The resulting model for changes in global pain was adjusted by time, treatment group, BMI, and age (the last one was only maintained for the absolute difference). In the mITT population, the odds ratio (OR) for MCII varied from 105.508 (95% CI: 22.572–493.176) to 73.449 (95% CI: 16.345–330.052) for absolute improvement (defined as 15 of 100 change) and from 243.594 (95% CI: 37.258–1592.648) to 243.594 (95% CI: 37.258–1592.648) for relative improvement (defined as 20% change). In the PP population, these figures varied from 98.514 (95% CI: 22.327–434.676) to 64.321 (95% CI: 16.14–256.33) for absolute improvement and from 249.445 (95% CI: 43.107–1443.438) to 160.3 (95% CI: 30.8–834.5) for relative improvement. BMI was not significant for models considering the WOMAC function subscale.

Overall, 67.4% of patients in the mITT population and 70.6% in PP took acetaminophen as rescue medication during the follow-up period, with no differences between groups.

Safety
Adverse reactions were all related to the administration procedure, and experienced by 3.5% of the patients: six cases
Table 1  Demographic and osteoarthritis baseline characteristics of study groups

<table>
<thead>
<tr>
<th></th>
<th>HA (n=97)</th>
<th>BM (n=98)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>59 (60.8)</td>
<td>57 (58.2)</td>
<td>ns</td>
</tr>
<tr>
<td>Age, years</td>
<td>62.7 (0.6)</td>
<td>62.8 (0.6)</td>
<td>ns</td>
</tr>
<tr>
<td>Age, distribution</td>
<td></td>
<td></td>
<td>ns</td>
</tr>
<tr>
<td>&lt;65 years</td>
<td>66 (68.0)</td>
<td>64 (65.3)</td>
<td></td>
</tr>
<tr>
<td>≥65 years</td>
<td>31 (32.0)</td>
<td>34 (34.7)</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.3 (0.5)</td>
<td>26.3 (0.4)</td>
<td>0.002</td>
</tr>
<tr>
<td>BMI, distribution</td>
<td></td>
<td></td>
<td>0.038</td>
</tr>
<tr>
<td>Normal weight</td>
<td>23 (23.7)</td>
<td>36 (36.7)</td>
<td></td>
</tr>
<tr>
<td>Overweight</td>
<td>35 (36.1)</td>
<td>38 (38.8)</td>
<td></td>
</tr>
<tr>
<td>Obesity type I</td>
<td>39 (40.2)</td>
<td>24 (24.5)</td>
<td></td>
</tr>
<tr>
<td><strong>OA baseline characteristics</strong></td>
<td></td>
<td></td>
<td>ns</td>
</tr>
<tr>
<td>Kellgren–Lawrence Grade, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>62 (63.9)</td>
<td>65 (66.6)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>35 (36.1)</td>
<td>33 (33.7)</td>
<td></td>
</tr>
<tr>
<td>Painful knee n (%)</td>
<td></td>
<td></td>
<td>ns</td>
</tr>
<tr>
<td>Right</td>
<td>45 (46.4)</td>
<td>48 (49.0)</td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>40 (41.2)</td>
<td>38 (38.8)</td>
<td></td>
</tr>
<tr>
<td>Both</td>
<td>12 (12.4)</td>
<td>12 (12.2)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BM, betamethasone; BMI, body mass index; HA, hyaluronic acid; ns, nonsignificant; OA, osteoarthritis; SD, standard deviation.

of pain (four in the group treated with HA and two in BM) and one erythema in the HA group. Effusion was detected in 3.5% of the patients (five patients in the HA group) when attending the second (three patients), third (one patient), and fifth (one patient) injection, and two in the BM group when attending for the second injection.

**Discussion**

This clinical trial comparing HA and BM showed remarkable long-term improvement in knee OA symptoms after treatment in both groups, with statistical and clinical differences favoring HA (P<0.0001).

Since Hollander reported great clinical response to IA hydrocortisone injections in the 1950s, IA CS injections have become a notable rheumatologic practice for the management of articular and periarticular inflammatory and pain conditions. Several formulations of CS are used in clinical practice, and though, on one hand, numerous investigations have been conducted, on the other, there is a lack of consensus in identifying variables such as the optimal CS agent or the dose and dosing frequency for OA treatment. The preferences vary geographically without a clear rationale, and current usage patterns are very often determined by the individual practitioner’s opinion.

The IA HA injections for knee OA have only been used in humans during the last 30 years, and have become widely employed since the early 1990s. Even though during this time multiple HA efficacy studies have been performed, studies with more than 6 months follow-up periods are rare, and, to our knowledge, there is only one clinical trial showing the carry-over effect of HA after repeated cycles of injections, lasting for at least 1 year. Several studies in knee OA have been carried out in order to compare the effects of IA HA and CS. These studies have found favorable results with both treatments, but very often they had short follow-up periods, making it difficult to rate one method above the other. A recent meta-analysis concluded that, from baseline to week 4, CS appeared to be relatively more effective in pain relief than HA, but beyond week 8, HA showed greater efficacy. Nevertheless, we found out that some studies, with up to 6 months follow-up and conducted with HAs of different molecular weight, did not find differences between both treatments at the end of the study.

Consequently, our work had a double purpose: the evaluation of both treatments over a long follow-up period, and analysis of the results in terms of not only statistical differences but also clinical significance. In our study and from the first evaluation visit after the interventions, we found a significant improvement in both groups compared to baseline in terms of VAS pain and WOMAC score. At 3 months, the data suggest that BM group had greater reduction in global pain while all WOMAC subscales including pain suggest greater improvement in the HA group compared to the BM group. As for the higher reduction in global pain observed in the BM group, it has been reported that CS have a short-term effect on pain but have no effect on function,
Table 2 Raw values of pain and WOMAC, mean ± SD (95% CI) at baseline and follow-up (mITT)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>3 m</th>
<th>6 m</th>
<th>9 m</th>
<th>12 m</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA</td>
<td>6.1±4.6*</td>
<td>3.1±0.9</td>
<td>2.2±1.0</td>
<td>2.1±1.1</td>
<td>2.4±1.2</td>
</tr>
<tr>
<td>BM</td>
<td>6.6±.103</td>
<td>3.1±0.9</td>
<td>2.2±1.0</td>
<td>2.1±1.1</td>
<td>2.4±1.2</td>
</tr>
<tr>
<td>Global pain</td>
<td>6.1±4.6*</td>
<td>3.1±0.9</td>
<td>2.2±1.0</td>
<td>2.1±1.1</td>
<td>2.4±1.2</td>
</tr>
<tr>
<td>WOMAC</td>
<td>7.0±3.3*</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
</tr>
<tr>
<td>Function</td>
<td>13.5±4.2</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
</tr>
<tr>
<td>Stiffness</td>
<td>5.6±3.1</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
<td>3.4±0.5</td>
</tr>
</tbody>
</table>

Notes: *P<0.0001 in favor of HA, **P<0.0001 in favor of BM.

Abbreviations: HA, hyaluronic acid; BM, betamethasone; CI, confidence interval; mITT, modified intention to treat; SD, standard deviation; WOMAC, Western Ontario McMaster University Osteoarthritis Index.

Like any research work, our work has some limitations and it is important to mention them. First, BMI was significantly higher in the HA group, with more obesity type I patients, so a priori this could prejudice the results obtained in this group. The GLM results showed that function was not affected, whereas with reference to pain the GLM analysis showed a positive effect of HA, which, a priori, could be considered a contradiction. Secondly, the participating patients showed differences in some OA symptoms at baseline. In our opinion, in both cases the large differences found between groups in all the comparisons whereas HA products can provide a more durable response with relief of pain and improvement in function, although the onset of these effects is slower. In this sense, our results would be in line with the behavior that could be expected for both products. On the other hand, it has been reported that the WOMAC pain subscale is highly related to physical function, so it does not seem strange that WOMAC pain goes on the same line as WOMAC function subscale, and differences with global pain should not be disregarded, as occurred in our study.

From this point (3 months) onward, the efficacy of BM decreased and resulted in significant statistical differences in favor of HA, which continued up to the end of the study.

When the results were also analyzed in terms of MCII by applying the cutoffs for absolute and relative change for pain and function, we did not find any difference between groups up to the 6 months follow-up, which could be in line with the studies mentioned that found longer efficacy periods for CS. Nevertheless, from this visit onward, the values in the BM group showed a dramatic decrease to the extent that at 9 months the percentage of patients showing an MCII for pain and function were 87.6% in the HA group and only 10.2% for BM (P<0.0001). The results in the HA group remained constant at 12 months.

Previous studies and meta-analyses have shown the efficacy versus placebo of HA or CS have compared both treatments in the short term. The aim of this study was to compare the efficacy of both treatments in the long term and using a different approach. To the best of our knowledge, this is the first study to compare CS and HA in terms of clinical improvement. The importance of defining a minimum important improvement to use in clinical trials is widely accepted. This approach will be most helpful when interpreting the results and addition of useful information for daily practice in order to provide information that is complementary to the conventional presentation of results at the group level (mean changes in scores).

Like any research work, our work has some limitations and it is important to mention them. First, BMI was significantly higher in the HA group, with more obesity type I patients, so a priori this could prejudice the results obtained in this group. The GLM results showed that function was not affected, whereas with reference to pain the GLM analysis showed a positive effect of HA, which, a priori, could be considered a contradiction. Secondly, the participating patients showed differences in some OA symptoms at baseline. In our opinion, in both cases the large differences found between groups in all the comparisons whereas HA products can provide a more durable response with relief of pain and improvement in function, although the onset of these effects is slower. In this sense, our results would be in line with the behavior that could be expected for both products. On the other hand, it has been reported that the WOMAC pain subscale is highly related to physical function, so it does not seem strange that WOMAC pain goes on the same line as WOMAC function subscale, and differences with global pain should not be disregarded, as occurred in our study.

From this point (3 months) onward, the efficacy of BM decreased and resulted in significant statistical differences in favor of HA, which continued up to the end of the study.

When the results were also analyzed in terms of MCII by applying the cutoffs for absolute and relative change for pain and function, we did not find any difference between groups up to the 6 months follow-up, which could be in line with the studies mentioned that found longer efficacy periods for CS. Nevertheless, from this visit onward, the values in the BM group showed a dramatic decrease to the extent that at 9 months the percentage of patients showing an MCII for pain and function were 87.6% in the HA group and only 10.2% for BM (P<0.0001). The results in the HA group remained constant at 12 months.

Previous studies and meta-analyses have shown the efficacy versus placebo of HA or CS have compared both treatments in the short term. The aim of this study was to compare the efficacy of both treatments in the long term and using a different approach. To the best of our knowledge, this is the first study to compare CS and HA in terms of clinical improvement. The importance of defining a minimum important improvement to use in clinical trials is widely accepted. This approach will be most helpful when interpreting the results and addition of useful information for daily practice in order to provide information that is complementary to the conventional presentation of results at the group level (mean changes in scores).
made during follow-ups and the consistency of the results across the study minimize the possible risk of bias in their interpretation.

Overall, a significant number of patients (67.4%) took acetaminophen as rescue medication during the follow-up period, with no differences between groups. The patients were asked at every assessment visit about the consumption, and contingency analyses within group and between groups concluded that the use of rescue medication did not interfere with the assessment of the clinical outcome. The administration of glucosamine and meloxicam for 1 month, and thereafter glucosamine and chondroitin for one additional month concomitantly to IA injections, could be a limitation to our study. This procedure is based on our usual clinical practice, and it was decided to keep this scheme in the protocol as well, in addition to the study interventions. However, these treatments were administered to all patients, and the time elapsed between the discontinuation of the treatments and the first evaluation visit was considered sufficient.

Adverse reactions were rare and related to the administration procedure, concluding that both treatments were safe and well tolerated, in accordance with other publications. A recent meta-analysis showed negative conclusions about the safety profile of HA in knee OA. Such conclusions result from a questionable selection of the evidence; the methodological procedures used in the analyses of safety have been also questioned in a later review. This review found that only two serious adverse events from only one of the studies analyzed (out of 71 studies) should be reported as related to HA. Moreover, the task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) does not endorse the negative results of the meta-analysis. With the current data, it can be

Table 3 Mean percentage of improvement expressed as percentage of decrease in the score relative to baseline ± SD (95% CI) in Global Pain and WOMAC (mITT)

<table>
<thead>
<tr>
<th></th>
<th>3 m HA</th>
<th>3 m BM</th>
<th>6 m HA</th>
<th>6 m BM</th>
<th>9 m HA</th>
<th>9 m BM</th>
<th>12 m HA</th>
<th>12 m BM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global pain</td>
<td>48.5±13.5</td>
<td>66.3±15.0*</td>
<td>60.6±14.8</td>
<td>39.6±12.6</td>
<td>41.2±16.4</td>
<td>14.4±17.8</td>
<td>33.6±12.4</td>
<td>8.2±4.8</td>
</tr>
<tr>
<td>WOMAC Total</td>
<td>68.6±8.9</td>
<td>49.5±5.4</td>
<td>73.7±9.7</td>
<td>37.9±5.2</td>
<td>52.6±7.9</td>
<td>12.9±6.9</td>
<td>46.2±9.3</td>
<td>12.9±6.2</td>
</tr>
<tr>
<td>Pain</td>
<td>83.7±15.7</td>
<td>49.9±14.8</td>
<td>90.0±14.8</td>
<td>33.3±17.9</td>
<td>52.8±15.7</td>
<td>13.2±14.0</td>
<td>44.1±19.6</td>
<td>12.7±14.3</td>
</tr>
<tr>
<td>Function</td>
<td>63.9±8.7</td>
<td>48.4±7.9</td>
<td>68.1±8.8</td>
<td>39.2±7.8</td>
<td>52.8±8.6</td>
<td>13.2±9.9</td>
<td>47.5±9.2</td>
<td>12.2±8.8</td>
</tr>
<tr>
<td>Stiffness</td>
<td>67.6±27.5</td>
<td>57.5±28.9***</td>
<td>79.5±23.6</td>
<td>28.7±4.9</td>
<td>44.3±22.3</td>
<td>6.5±4.8</td>
<td>33.8±22.3</td>
<td>10.5±33.8</td>
</tr>
</tbody>
</table>

Notes: P-values: <0.0001 in favor of HA in all the comparison between groups except for *P<0.0001 in favor of BM, **P<0.0012 in favor of HA.
Abbreviations: BM, betamethasone; CI, confidence interval; HA, hyaluronic acid; mITT, modified intention to treat; SD, standard deviation; WOMAC, Western Ontario McMaster University Osteoarthritis.

Figure 2 Percentage of patients with MCII (15 points) in pain and function during the study by treatment group (mITT) (n=97 patients in HA and n=98 in BM at all time points).

Note: *P<0.003, **P<0.001.
Abbreviations: BM, betamethasone; HA, hyaluronic acid; m, months; MCII, Minimal Clinically Important Improvement; mITT, modified intention to treat.

Figure 3 Percentage of patients with MCII (20%) in pain and function during the study by treatment group (mITT) (n=97 patients in HA and n=98 in BM at all time points).

Note: *P<0.001.
Abbreviations: BM, betamethasone; HA, hyaluronic acid; m, months; MCII, Minimal Clinically Important Improvement; mITT, modified intention to treat.
concluded that intra-articular injections of HA are safe and do not place the individuals at risk.

The results of our study show that both treatments are effective in controlling OA symptoms but the pattern varies over time. The two treatments showed equal efficacy at initial follow-ups, but HA demonstrated a clearly superior long-term effectiveness than BM, with sustained clinical efficacy levels in a significant number of patients 1 year after administration.

Acknowledgments
The authors would like to thank Ignacio Méndez, Noelia Alfaro, and Belén San José from OXON Epidemiology Ltd for the statistical analysis of the results.

Disclosure
The authors report no conflicts of interest in this work.

References
7. The authors report no conflicts of interest in this work.


